Stockscreener 앱 받기
0.00
100.00%
-18.11
전일 마감가:
$18.11
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$N/A
수익:
-
순이익/손실:
$149.05M
주가수익비율:
0.00
EPS:
1.9846
순현금흐름:
$-6.05M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$19.00
갈레라 테라 Stock (GRTX) Company Profile
Compare GRTX vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GRTX
Galera Therapeutics Inc
|
0.00 | 0 | 0 | 149.05M | -6.05M | 1.9846 |
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
789.45 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
158.07 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
995.77 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
196.94 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
갈레라 테라 Stock (GRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-10 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-10-19 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2021-10-19 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-12-07 | 개시 | H.C. Wainwright | Buy |
| 2019-12-02 | 개시 | BTIG Research | Buy |
| 2019-12-02 | 개시 | BofA/Merrill | Buy |
| 2019-12-02 | 개시 | Citigroup | Buy |
| 2019-12-02 | 개시 | Credit Suisse | Neutral |
모두보기
갈레라 테라 주식(GRTX)의 최신 뉴스
Obsidian Therapeutics: A $1.1 Billion Valuation Leaves Little Margin For Error (OBX) - Seeking Alpha
Obsidian Therapeutics, Inc. SEC Filing (Sep 10, 2026) - Stock Titan
Obsidian Therapeutics initiated with an Outperform at William Blair - TipRanks
Galera Therapeutics Inc. (GRTX) Peer Comparison – Compare with Others - Value Research
[S-1] Obsidian Therapeutics, Inc. Files IPO Registration Statement - Stock Titan
Obsidian Therapeutics Merges with Galera Therapeutics - Labroots
Ikarian Capital (GRTX) reports 0% beneficial ownership of Galera Therapeutics in 13G/A amendment - Stock Titan
Obsidian Therapeutics (OBX) boosts cash with $350M PIPE and Galera merger - Stock Titan
Obsidian Therapeutics (OBX) outlines $350M PIPE, Galera mergers and CVR structure - Stock Titan
Obsidian Therapeutics (OBX) CFO Julie Feder reports stock options on 3.0M shares - Stock Titan
OBX SEC FilingsObsidian Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Obsidian Therapeutics (OBX): RA Capital discloses 5.96M-share, 9.7% position - Stock Titan
Galera Therapeutics, Inc. SEC Filing (Aug 10, 2026) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Galera Therapeutics (GRTX) CEO reports option and share disposition tied to merger - Stock Titan
Galera Therapeutics, Inc. (GRTX) details director option change - Stock Titan
Galera Therapeutics (NASDAQ: GRTX) details conversions tied to Obsidian merger - stocktitan.net
Galera Therapeutics (NASDAQ: GRTX) director’s options converted in merger - Stock Titan
Galera Therapeutics (GRTX) CAO exits 10,000 stock options in merger - Stock Titan
Galera Therapeutics (GRTX) director details merger-driven stock and option moves - stocktitan.net
Obsidian Therapeutics’ Nasdaq Listing via Galera Reverse Merger Yields 170% Gain to RTW Bio’s Valuation - Kalkine Media
Galera Therapeutics, Inc. SEC Filing (Aug 4, 2026) - Stock Titan
GALERA THERAPEUTICS, INC : PIPER SANDLER INITIATES COVERAGE WITH OVERWEIGHT RATING; PRICE TARGET $42 - Bitget
Obsidian Therapeutics Completes Merger and Leadership Transition - TipRanks
Galera Therapeutics Completes Merger with Obsidian Therapeutics and Becomes Obsidian Therapeutics, Inc - Minichart
Galera Therapeutics, Inc. Announces Resignation of Joel Sussman as the Principal Financial and Accounting Officer - marketscreener.com
Galera (NASDAQ: GRTX) closes Obsidian merger, sets 80%/95% CVRs - Stock Titan
Galera Therapeutics, Inc. (GRTXD) Latest Press Releases & Corporate News - Yahoo! Finance Canada
Obsidian Completes Galera Merger with $350M Private Placement Financing - Contract Pharma
Obsidian Therapeutics completes merger with Galera By Investing.com - Investing.com Nigeria
Obsidian Therapeutics Completes Galera Merger and $350 Million Financing - citybiz
Obsidian Therapeutics completes merger with Galera - Investing.com
Galera Therapeutics Announces Major PIPE Financing and CVRs - tipranks.com
Galera Therapeutics (NASDAQ: GRTX) raises $350M PIPE, issues CVRs before merger - Stock Titan
Galera Therapeutics, Inc. (GRTXD) Stock Price, News, Quote & History - Yahoo Finance
GRTXD Interactive Stock Chart | Galera Therapeutics, Inc. Stock - Yahoo Finance
Galera Therapeutics, Inc. (GRTXD) insider ownership and holdings - Yahoo Finance Singapore
Galera Therapeutics, Inc. (GRTXD) - Yahoo! Finance Canada
Galera Therapeutics, Inc. (GRTXD) Company Profile & Facts - Yahoo! Finance Canada
Galera Therapeutics, Inc. (GRTXD) Stock Major Holders - Yahoo! Finance Canada
Galera Therapeutics, Inc. (GRTXD) Stock Forum & Discussion - Yahoo! Finance Canada
GRTXD: Galera TherapeuticsInsider Transations - Zacks Investment Research
Galera Therapeutics (GRTXD) Pe Ratio (TTM) - Zacks Investment Research
Gross profit of Galera Therapeutics, Inc. – OTC:GRTXD - TradingView
Cost of goods sold of Galera Therapeutics, Inc. – OTC:GRTXD - TradingView
All News for GRTXD : Galera Therapeutics - Zacks Investment Research
Cash flow from financing activities of Galera Therapeutics, Inc. – OTC:GRTXD - TradingView
Cash flow from investing activities of Galera Therapeutics, Inc. – OTC:GRTXD - TradingView
Free cash flow of Galera Therapeutics, Inc. – OTC:GRTXD - TradingView
Operating income of Galera Therapeutics, Inc. – OTC:GRTXD - TradingView
Non-controlling/minority interest of Galera Therapeutics, Inc. – OTC:GRTXD - TradingView
갈레라 테라 (GRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.79%
자본화:
|
볼륨(24시간):